The Management Board of Sygnis SA with its offices in Warsaw (hereinafter: the Company) informs that today it has received information that the last party has signed an annex to the consortium agreement, on the basis of which the Company has been joined to the consortium formed by the Lodz University of Technology (consortium leader), the Warsaw University of Technology and the Nicolaus Copernicus University in Torun for the implementation of the project entitled “New functional 3D printing MATerials for UROlogical needs” (acronym: MATURO 3D). The MATURO 3D project is already underway and aims to develop innovative materials for the reconstructive treatment of urethral defects in children and adults. The research conducted within the framework of this project is aimed at building a 3D bioprinter, which, together with the developed biosheets, will make it possible to produce 3D prints that will provide products for patients.
As part of the MATURO 3D project, the Company will be involved in research and development work involving the creation of a line for extruding new materials, and will be responsible for implementing and commercializing the scientific results of the entire MATURO 3D project.
The Board of Directors points out that by joining the above-mentioned consortium, the Company expands its portfolio of biotechnology projects based on hardware and new materials, and establishes new strategic cooperation, gaining access to know-how. In addition, the Company also gains the opportunity to enter the pan-European biotech product market with another proprietary product, which is in line with the Company’s strategy of multidirectional development.